Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy
<b>Background:</b> Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. <b>Methods:</b> In this study, we introduce a novel lipid nanopart...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/45 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587738192281600 |
|---|---|
| author | Yanru Feng Xintong Pan Ziqian Li Yue Li Ya’nan Sun Shaokun Yang Chaoxing He Yunjie Dang Lu Huang Bai Xiang |
| author_facet | Yanru Feng Xintong Pan Ziqian Li Yue Li Ya’nan Sun Shaokun Yang Chaoxing He Yunjie Dang Lu Huang Bai Xiang |
| author_sort | Yanru Feng |
| collection | DOAJ |
| description | <b>Background:</b> Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. <b>Methods:</b> In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (si<i>TNF-α</i>) using microfluidic technology, marking the first use of such a combination for RA therapy. <b>Results:</b> In LPS-stimulated RAW 264.7 cells, the nanoparticles effectively reduced inflammatory markers. When administered via an intra-articular injection in a rat model, they significantly decreased joint inflammation and demonstrated good biological safety. <b>Conclusions:</b> This pioneering approach highlights the potential of lipid nanoparticles as a dual-delivery platform for enhanced RA treatment through targeted intra-articular administration. |
| format | Article |
| id | doaj-art-c76424888c44416dbcfc1689948dba05 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-c76424888c44416dbcfc1689948dba052025-01-24T13:45:42ZengMDPI AGPharmaceutics1999-49232025-01-011714510.3390/pharmaceutics17010045Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis TherapyYanru Feng0Xintong Pan1Ziqian Li2Yue Li3Ya’nan Sun4Shaokun Yang5Chaoxing He6Yunjie Dang7Lu Huang8Bai Xiang9Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, ChinaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China<b>Background:</b> Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. <b>Methods:</b> In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (si<i>TNF-α</i>) using microfluidic technology, marking the first use of such a combination for RA therapy. <b>Results:</b> In LPS-stimulated RAW 264.7 cells, the nanoparticles effectively reduced inflammatory markers. When administered via an intra-articular injection in a rat model, they significantly decreased joint inflammation and demonstrated good biological safety. <b>Conclusions:</b> This pioneering approach highlights the potential of lipid nanoparticles as a dual-delivery platform for enhanced RA treatment through targeted intra-articular administration.https://www.mdpi.com/1999-4923/17/1/45lipid nanoparticleco-deliveryhydroxychloroquinesi<i>TNF-α</i>rheumatoid arthritis |
| spellingShingle | Yanru Feng Xintong Pan Ziqian Li Yue Li Ya’nan Sun Shaokun Yang Chaoxing He Yunjie Dang Lu Huang Bai Xiang Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy Pharmaceutics lipid nanoparticle co-delivery hydroxychloroquine si<i>TNF-α</i> rheumatoid arthritis |
| title | Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy |
| title_full | Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy |
| title_fullStr | Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy |
| title_full_unstemmed | Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy |
| title_short | Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy |
| title_sort | innovative lipid nanoparticles co delivering hydroxychloroquine and sirna for enhanced rheumatoid arthritis therapy |
| topic | lipid nanoparticle co-delivery hydroxychloroquine si<i>TNF-α</i> rheumatoid arthritis |
| url | https://www.mdpi.com/1999-4923/17/1/45 |
| work_keys_str_mv | AT yanrufeng innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT xintongpan innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT ziqianli innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT yueli innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT yanansun innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT shaokunyang innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT chaoxinghe innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT yunjiedang innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT luhuang innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy AT baixiang innovativelipidnanoparticlescodeliveringhydroxychloroquineandsirnaforenhancedrheumatoidarthritistherapy |